Cite
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
MLA
Chen, Rong, et al. “Pharmacokinetic Parameter Driven Outcomes Model Predicts a Reduction in Bleeding Events Associated with BAY 81-8973 versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method in a Chinese Healthcare Setting.” BMC Medical Research Methodology, vol. 22, no. 1, Aug. 2022, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12874-022-01659-w.
APA
Chen, R., Gultyaev, D., Lister, J., Han, R., Hu, N., Malacan, J., Solms, A., Vashi, P., O’Hara, J., & Hu, S. (2022). Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting. BMC Medical Research Methodology, 22(1), 1–9. https://doi.org/10.1186/s12874-022-01659-w
Chicago
Chen, Rong, Dmitry Gultyaev, Johanna Lister, Rong Han, Nan Hu, Jean Malacan, Alexander Solms, Parth Vashi, Jamie O’Hara, and Shanlian Hu. 2022. “Pharmacokinetic Parameter Driven Outcomes Model Predicts a Reduction in Bleeding Events Associated with BAY 81-8973 versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method in a Chinese Healthcare Setting.” BMC Medical Research Methodology 22 (1): 1–9. doi:10.1186/s12874-022-01659-w.